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Abstract
Objectives: Successful control of the HIV/AIDS pandemic requires reduction of HIV-1 transmission at sexually-exposed
mucosae. No prevention studies of the higher-risk rectal compartment exist. We report the first-in-field Phase 1 trial of a
rectally-applied, vaginally-formulated microbicide gel with the RT-inhibitor UC781 measuring clinical and mucosal safety,
acceptability and plasma drug levels. A first-in-Phase 1 assessment of preliminary pharmacodynamics was included by
measuring changes in ex vivo HIV-1 suppression in rectal biopsy tissue after exposure to product in vivo.
Methods: HIV-1 seronegative, sexually-abstinent men and women (N=36) were randomized in a double-blind, placebo-
controlled trial comparing UC781 gel at two concentrations (0.1%, 0.25%) with placebo gel (1:1:1). Baseline, single-dose
exposure and a separate, 7-day at-home dosing were assessed. Safety and acceptability were primary endpoints. Changes in
colorectal mucosal markers and UC781 plasma drug levels were secondary endpoints; ex vivo biopsy infectibility was an
ancillary endpoint.
Results: All 36 subjects enrolled completed the 7–14 week trial (100% retention) including 3 flexible sigmoidoscopies, each
with 28 biopsies (14 at 10 cm; 14 at 30 cm). There were 81 Grade 1 adverse events (AEs) and 8 Grade 2; no Grade 3, 4 or
procedure-related AEs were reported. Acceptability was high, including likelihood of future use. No changes in mucosal
immunoinflammatory markers were identified. Plasma levels of UC781 were not detected. Ex vivo infection of biopsies using
two titers of HIV-1BaL showed marked suppression of p24 in tissues exposed in vivo to 0.25% UC781; strong trends of
suppression were seen with the lower 0.1% UC781 concentration.
Conclusions: Single and 7-day topical rectal exposure to both concentrations of UC781 were safe with no significant AEs,
high acceptability, no detected plasma drug levels and no significant mucosal changes. Ex vivo biopsy infections
demonstrated marked suppression of HIV infectibility, identifying a potential early biomarker of efficacy. (Registered at
ClinicalTrials.gov; #NCT00408538)
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Efforts to reduce the sexual transmission of HIV-1 are pivotal to
controlling the AIDS pandemic. Sustained plasma suppression
reduces transmission but trials of HIV-specific vaccines and topical
microbicides have been challenging in heterosexual couples and
men who have sex with men (MSM) populations, especially given
the still-poorly understood immune responses at the sexually-
exposed mucosal portals of virus entry [1–9]. The recent results
from both the Phase IIb CAPRISA 004 Trial of vaginally-applied
1% tenofovir gel and the Phase III iPrEx Trial of oral Truvada
tablets (a co-formulation of tenofovir disoproxil fumarate and
emtricitabine) have been exciting, first-time achievements in HIV
prevention [10,11].
Microbicides have been advanced as a topical mode of reducing
HIV-1 transmission ‘‘per sexual act.’’ While discussed as a topical
version of PrEP [12], use of topical microbicides is intended to
provide a safe, acceptable, affordable form of protection from
HIV-1 transmission, providing receptive partners (women and
men) with options, especially when condom use is non-negotiable
[13]. The spermicidal and contraceptive vaginal agent, nonox-
ynol-9 (N9) was demonstrated, post-approval, to create an
increased risk for HIV-1 acquisition with frequent vaginal use.
Significant epithelial sloughing was seen when applied rectally.
This experience identified newer safety parameters to consider
when evaluating microbicidal agents [14–16]. Until recently,
clinical trial efforts have focused on vaginal transmission with
mostly disappointing results [17–21]. A first-in-field success,
CAPRISA 004 utilized a reverse-transcriptase inhibitor (1%
tenofovir) gel applied 12 hours before and after vaginal inter-
course. The study demonstrated a .50% reduction in HIV-1
transmission in those women using the gel for .80% of episodes
[10,11]. Equally exciting, in different risk groups, was the recent
iPrEx trial demonstration of 44% reduction of HIV-1 transmission
in ,2500 higher-risk MSM at 11 study sites worldwide [11]. As in
the CAPRISA trial, when the inherently difficult issue of
adherence is teased apart, sub-analyses suggest the prevention
rate may be 50% or higher. Both studies successfully demonstrated
proof-of-concept for topical microbicides.
Rectal transmission of HIV-1 is thought to be 20–200-times
more likely per sexual act than vaginal transmission, perhaps
related to the single-cell epithelial lining and extensive, activated
resident immunocyte populations [1–7,22,23]. Receptive anal
intercourse (RAI) is highly prevalent among MSM and also in
heterosexual sexual partnerships [24–30]. It is anticipated that
when the mucosa is co-infected (such as with HSV) or significant
trauma, the rate of rectal transmission per sex act would markedly
increase [31–34].
This report describes the first IND-supported Phase 1 safety
trial of two concentrations of UC781 (0.25% and 0.1%) as a rectal
microbicide. UC781 is a potent non-nucleoside reverse transcrip-
tase inhibitor (NNRTI) which binds tightly to HIV-1 RT [35–40],
has activity against a wide range of subtype HIV-1 isolates and is
poorly absorbed from mucosal surfaces with systemic limited
bioavailability. UC781 displays in vitro nanomolar range EC50
activity against wild type HIV-1 virus and little to no cytotoxic
effect on cell lines and primary cells. In pre-clinical studies of
human cervical and colorectal explants pre-incubated with
UC781, R5 HIVBaL was markedly suppressed, decreasing the
infection in migrating lymphoid cells [41,42]. UC781 added in vitro
showed 100% inhibition of HIVBaL at 3.3 mg/ml and 90%
inhibition at 0.33 mg/ml. These infectious doses are thought to be
far in excess of ejaculate concentrations [43–45]. For comparison,
the delivered doses (empirically assuming a 106dilution by rectal
fluids) in this trial for the 0.1% gel was a dose of 3.5 mg in 3.5 ml
(1000 mg/ml) and for the 0.25% gel, a dose of 8.75 mg in 3.5 ml
(2500 mg/ml).
Two concentrations of UC781 gel (0.10% and 0.25%)
formulated for topical vaginal application and demonstrating
safety in early dose-ranging vaginal safety studies [46–48] were
applied rectally in this study. The product was delivered using the
same applicator design as used in vaginal microbicide trials. The
novelty of this ‘‘first in field’’ study was facilitated by the HPTN-
056 study which established normative ranges and inter-subject
variabilities in a host of recently developed mucosal indices to
assess potential mucosal injury [49].
An innovative 2-stage trial design was used consisting of an
initial, single rectal application of either of the two concentrations
of UC781 or hydroxyethyl cellulose (HEC) placebo gel followed
several weeks later by 7 once-daily, self-administered rectal
applications. We have previously reported the acceptability
evaluations carried out in this trial [50]. Here we report the
clinical safety of vaginally-formulated UC781, plasma drug
concentrations, mucosal safety and the use of novel ex vivo biopsy
HIV-1 infection challenges of in vivo exposed tissue samples, Both
concentrations of UC781 were shown to be clinically safe by all
indices used with few Grade 2 and no Grade 3, 4 or procedure-
related AEs. Plasma levels of UC781 were not seen and no
significant mucosal abnormalities were detected. Remarkably, the
ex vivo HIV-1 infection of tissue biopsies showed marked
suppression with UC781 0.25%.
Methods
The study was designed by the investigators with collaborative
input from CONRAD and the NIAID/DAIDS/Prevention
Sciences Integrated Preclinical-Clinical Program (IPCP), as
stipulated in the award notice and reviewed by the U.S. Food
and Drug Administration (FDA). The study was approved by the
UCLA Office of the Human Research Protection Program
Institutional Review Board (UCLA IRB) and all subjects provided
written informed consent. The trial is registered at ClinicalTrials.-
gov, number NCT00408538 and is in compliance with the
CONSORT 2010 recommendations for reporting of trial results
(www.consort-statement.org) [51,52].
Study population
HIV-1 seronegative men and women between the ages of 18
and 64 (inclusive) with a history of consensual receptive anal
intercourse (RAI) at least once in lifetime were eligible for
screening. This was included to identify individuals with some
familiarity of sexual or product insertion per rectum. Lower risk of
HIV infection was supported by HIV screening tests for inclusion,
the additional inclusion criteria of willingness to be sexually
abstinent regarding rectal sex or any other rectal insertions one
week prior to treatment and one week before and following each
flexible sigmoidoscopy. Ongoing monitoring of plasma HIV RNA
further supported this. Exclusion criteria included HIV infection,
known inflammatory bowel disease or any other chronic
gastrointestinal disorder and/or history of significant gastrointes-
tinal bleeding as well as any allergies to methlyparaben,
propylparaben or sorbic acid.
Study Products
Two concentrations of UC781 (0.1% or 0.25% w/w),
Carbomer 974P, methylcellulose, glycerin, purified water and
common preservatives (methlyparaben and propylparaben), ad-
justed to pH 5.2, were prepared in vaginally-formulated, aqueous
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same type of applicators as used in UC781 vaginal microbicide
trials) were packaged, overwrapped and shipped directly to the
study site pharmacy. Each applicator contained either a dose of
3.5 mg in 3.5 ml (1000 mg/ml) for the 0.1% gel, a dose of 8.75 mg
in 3.5 ml (2500 mg/ml) for the 0.25% gel, or 3.5 g in 3.5 ml of
aqueous HEC (hydroxyethyl cellulose) gel, adjusted to pH 4.4, as
the placebo gel [53].
Study Design
This was a single site, blinded, multi-arm, two-treatment stage
Phase 1 trial using two established UC781 drug concentrations
and HEC placebo in 36 subjects in a 1:1:1 randomization
(Figure 1). The protocol for this trial and supporting CONSORT
checklist are available as supporting information; see Checklist S1
and Protocol S1. The first stage was a randomized single exposure,
directly applied by clinical personnel, with the subject remaining
supine for the 30 minute period until sample collection. The
second stage, assessed separately, was a randomized (same groups),
7-day cumulative exposure delivered by participants at home.
Participants were given a Product Use Log for the 7-day use and
were called daily to encourage use and recording of symptoms/
time of use.
The primary objectives of the study were to evaluate the safety
and acceptability of 0.1% and 0.25% UC781 vaginal microbicide
gel versus placebo when applied rectally.
The primary endpoints were (i) the frequency of $Grade 2
adverse events and (ii) extensive acceptability evaluations (reported
elsewhere [50]. The primary tool for safety assessments and
grading adverse events was the DAIDS AE Grading Table
Version 1.0, December 2004, Addenda 1 (female genital) and 3
(rectal-specific) Grading Tables for Use in Microbicide Studies
(http://rsc.tech-res.com/safetyandpharmacovigilance). AE grad-
ings are defined as symptoms causing no or minimal (Grade1),
causing greater than minimal (Grade 2) interference with or
causing inability to perform (Grade 3) usual social and functional
activities. Physical signs and laboratory values are graded similarly
to the ones listed in the main DAIDS AE Grading Table. Details
of demographics and adverse events are provided in Table S1 and
Table S2.
One secondary objective of the study was to determine whether
use of study products was associated with rectal mucosal damage.
Secondary endpoints included rectal epithelial sloughing, histopa-
thology, rectal microflora, fecal calprotectin, and a group of
‘‘mucosal immunotoxicity indices,’’ which included flow cytomet-
ric characterization of isolated mucosal mononuclear cells
(MMCs), secreted mucosal immunoglobulins, secreted rectal fluid
cytokines, mucosal tissue cytokine mRNA and susceptibility to
HIV infection of rectal tissue biopsies.
An additional secondary objective was to determine the
pharmacokinetics (PK) of UC781 vaginal microbicide gel admin-
istered rectally in a subset of participants. The endpoint was UC781
blood levels as an indicator of absorption of drug from the GI tract.
Enrollment was protocol-defined as having met initial, screening
criteria at Visit 1 (eligibility requirements, consent signing, STI
evaluations and baseline acceptability questionnaires answered via
CASI) and having been randomized post Visit 2. During Visit 2,
baseline sample collections and flexible sigmoidoscopy for each
subject’s baseline mucosal biopsy infectibility, PK as well as
additional acceptability assessments occurred. PK assessments for
UC781 were measured in a subset of enrolled, randomized
participants. All subject visits were at the UCLA Digestive
Diseases Clinic and/or UCLA Outpatient Endoscopy Suite.
Following enrollment, 36 subjects were randomized, in a double-
blind fashion, to one of the three treatment arms. Randomization
was performed in blocks of six, with each block containing two
assignment codes for each of the three treatment groups. A subset of
9 subjects (3 from each group) also participated in a PK sub-study,
which included 6 timepoints (pre-dosing, 0.25 hr, 2 hr, 4 hr, and
24 hr after the single dose, and 1 day post-daily dosing for 9 of the
36 study participants (3 participants in each study group: placebo,
0.25% UC781 and 0.1% UC781) were randomized for UC781
plasma levels for 24-hour PK (baseline/pre-dosing, 30 minute, 2, 4
and 24 hours following single exposure) and also single cumulative
level following 7-day dosing (total of 54 samples). Randomization
codes were generated by the study biostatistician using computer-
generated random numbers. Once generated, the UCLA investi-
gational pharmacy held primary responsibility for dispensing drug,
randomizing subjects and maintaining the blind.
Each participant had three flexible sigmoidoscopies for mucosal
biopsies and other sample collections: baseline (Visit 2), 30 min-
utes post single topical exposure (Visit 3) and the morning
following completion of 7 daily at-home topical exposures (Visit 5).
Rectosigmoid colonic biopsies (referred to hereafter as ‘‘colonic
biopsies’’) were collected endoscopically using large cup biopsy
forceps via a flexible sigmoidoscope as previously described
[49,54]. The first set of colorectal biopsies were then acquired at
10 cm from the anal verge and then at 30 cm (14 biopsies
acquired at each site; 28 total biopsies per visit).
Each study visit to the endoscopy suite for flexible sigmoidoscopy
had an established sequence to minimize confounding of endpoint
results. Phlebotomy for safety laboratories as well as UC781 PK
plasma samples occurred first (pre-exposure at Visit3 and then at
30 minutes, 2 hr, 4 hr and 24 hr); rectal sponges (ULTRACELLH
Aspen Surgical #40415, Caledonia, Michigan) then were applied
via plastic anoscope as previously described [55] for collection of
mucosal secreted immunoglobulins and cytokines as well as rectal
microflora.ANormosolHpreparatoryenemawasadministeredwith
participants evacuating enema contents into a toilet-seat plastic
Figure 1. Study Flow Diagram.
doi:10.1371/journal.pone.0023243.g001
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shipment to Genova Diagnostics, Asheville, NC). Microflora
samples were shipped same day for characterization to Dr. Sharon
Hillier’s Laboratory at Magee-Womens Research Institute, Pitts-
burgh, PA. Participants were then taken to the endoscopy room.
Following digital examination, the flexible sigmoidoscope was
introduced to a distance of 5 cm in the rectal vault where 50 cc of
NormosolH solution was slowly infused. Following 30 seconds, at
least 25–30 ml of lavage fluid was aspirated through the endoscope
to a collection trap vial to assessepithelial sloughing. The endoscope
was then advanced to collect biopsies as described above.
Endoscopic pictures/grading were not recorded due to the known
variability of the colorectal lining in health.
Behavioral and acceptability measures (primary
endpoint)
All participants completed the Baseline Behavioral Question-
naire (BBQ) prior to Visit 3. Product Acceptability Questionnaires
(PAQs) were completed after the 7-day exposure. The PAQ
included both close-ended and open-ended questions, assessed
using a password-protected Web-based survey, enabling direct
data entry. An extensive, final 1-hour, in-depth acceptability
interview was conducted. Detailed methods and results of this
portion of this trial have been published [50].
Indicators of rectal mucosal damage
A diverse panel of mucosal assessments to evaluate potential
injury or significant alteration from baseline immune parameters
was used to detect changes post-gel exposure compared to baseline
findings within individual subjects and between study groups [49].
The broad profile of mucosal markers of inflammation/injury is
included based on several years of development, optimization and
determination of in vivo stability, reproducibility and variability.
The clinical relevance of two-fold or more changes in any of these
parameters is not known but the absence of any changes provides
a degree of confidence of non-injury [49]. The assays used to
monitor mucosal injury, activation and/or inflammation are
described below. Following the methods is a listing of which
samples were collected at which visits.
Fecal calprotectin
During enhanced mucosal inflammation, intestinal granulocytes,
containing large amounts of the cytoplasmic protein calprotectin,
migrate through the mucosal epithelia and granulocyte-derived
calprotectin can be found in feces, providing a useful indirect index
of mucosal inflammation [56,57]. Fecal calprotectin levels correlate
well with disease activity in Crohn’s disease and ulcerative colitis
[58,59]and were utilized here to indirectly detect acute inflamma-
tion. Stool was collected using a kit with mailing materials (Genova
Diagnostics, Asheville, NC). A 20 ml stool sample was collected
from participant’s enema evacuations and mailed same day.
Reported results from the company have a range with ,50 mg/
ml=normal; greater than 50 mg/ml to 500 mg/ml equating to
varying levels of inflammation. Fecal calprotectin assays have a
sensitivity of 96% in discriminating between healthy controls
(2 mg/l; 95% CI 2–3 mg/l) and subjects with active inflammatory
bowel disease (91 mg/l; 95% CI 59–105 mg/1) [56,57].
Rectal secretions of immunoglobulins and cytokines
collected by sponges
Rectal secretions were collected using 4 cellulose sponges
(ULTRACELLH,AspenSurgicalCaledonia,Michigan)forsecreted
immunoglobulins (2 dedicated sponges) and secreted cytokines (2
dedicated sponges) per collection event, as previously reported
[49,60]. Sterile sponges were pre-moistened with 50 ml ofphosphate
buffered saline (Gibco BRL, Gaithersburg, MD) and attached to an
adapted 2 ml plastic transfer pipette (Fisher Scientific, Pittsburgh,
PA). Two pipettes with attached sponges were introduced into the
rectum via the anoscope and held against the rectal mucosa under
direct vision for 5 minutes, then placed on ice until freezing at 280u
for batch processing. Samples with visible blood were discarded.
Sponge tips were transferred to a 2 ml Spin-X column (Corning,
Corning, NY), from which the acetate membrane had been
removed. This was repeated for the second set of two sponges.
Absorbed rectal secretions were eluted twice with a total volume of
250 ml of cold elution buffer (PBS containing 0.25% BSA (Sigma
Chemicals, St Louis, MO), 1% Igepal (Sigma Chemicals, St Louis,
MO) and 16 protease inhibitor cocktail (Sigma Chemicals, St
Louis, MO) from the sponges by centrifugation (10,000 rpm,
30 minutes at 4 degrees). The recovered eluate was transferred to a
pre-weighed 1.5 ml Eppendorf tube (Fisher Scientific, Pittsburgh,
PA) and re-weighed. The recovered volume of secretion was
calculated by subtracting the recovered volume from that recovered
from control sponges that were run in parallel. Duplicate samples
were pooled, (usually yielding 400 ml), frozen and retrieved in
batches for further analysis.
Total IgG and total IgA were quantified (in duplicate) in the
eluted rectal secretions by ELISA [54] and results expressed as ng/
ml. Values in ng/ml were extrapolated from the relevant standard
curves and means calculated for each sample. The Coomassie
Dry
TM Blue Protein Assay (Pierce, Rockford, IL) was used to
extrapolate the quantity of total protein expressed as ng/ml [49].
Cytokine samples were quantified (pg/ml) using 50 mli na
LincoplexH Human cytokine/chemokine multiplex immunoassay
kit (used in BioRad LuminexH 100 System multiplexing array
instrument).Sevensecretedcytokineproteinswerequantifiedinpg/
ml (RANTES, MIP-1a, TNF-a, IFNc, IL-12 (p-40), IL-6, IL-1b).
Microflora
Rectal specimens obtained per rectum with a sterile cotton swab
were placed in an anaerobic transport tube (Port-a-Cul; Becton-
Dickinson Corp., Cockeysville, MD) and shipped by overnight
mail to Dr. Sharon Hillier’s Laboratory at Magee-Womens
Research Institute, Pittsburgh, PA. The swab was removed,
placed into 0.9 ml of buffered salt solution and vortexed to release
fluid and processed as previously reported [7]. Plates were
incubated in an anaerobic chamber for 72–96 hours for detection
of anaerobes; agar plates for aerobic bacteria were evaluated after
48 hours of incubation at 37uCi n6 %C O 2. Given the enormous
variety of normally-present bacteria in the colon and the unknown
variations related to diet and time, the bacterial groups selected for
monitoring before and after product exposure was based on a
FDA defined and accepted panel. These microflora are identified
in Table 1. Changes in bacterial frequencies and concentrations
within exposed individuals as well as between study groups were
examined between baseline visit and following the 7-day exposure
(which included any changes occurring after the single dose
exposure). Results are quantified by colonization growth on a scale
from 0–4 as follows: 0=no growth; 1=10
3 cfu/ml; 2=10
5 cfu/
ml; 3=10
6 cfu/ml 4=10
7 cfu/ml. Raw means and SDs were
computed by time (before or/after gel use), using McNemar’s test
for evaluating paired changes in colonization status [61,62].
Epithelial sloughing
Collected lavage fluid (.25 ml) was transported on ice to the
laboratory. Using a protocol adapted from Patton and Phillips
[14,63], the fresh lavage samples were placed in a 100615 mm
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with attached CANON Powershot A630 camera, to count
epithelial sheets. The sheets were measured in quadrants using a
permanent ruler, affixed to the platform, under the Petri dish, as
previously reported [14,63]. Positive findings were defined as a
clear, spongy, elastic piece of cellular material (with nucleus) at
least 2 mm in size. As epithelial sloughing does not have an
absolute, quantifiable threshold, the previously used scoring system
of 0–4 was used. Each of four Petri-dish quadrants was scored as
either 0 or 1, (absence or presence of epithelial sheets) for a total
score from 0–4.
Histology
Histopathological scoring of inflammation was carried out on
oriented, formalin-fixed paraffin-embedded, hematoxylin- and
eosin-stained tissue biopsies. Colonic mucosal biopsy samples were
obtained at both 10 cm and 30 cm (measured by endoscopic
markings) from the dentate line. A pathologist with specialty
training in gastrointestinal pathology, blinded to sample group,
performed the batched, qualitative (scale: 0–5) histological
assessments. A validated, qualitative scoring scale of chronic
active inflammation used in ulcerative colitis trials previously
adapted and reported for baseline mucosal indices in microbicidal
studies [49] was used.
Isolation of mucosal mononuclear cells and flow
cytometry
MMCs were isolated from intestinal biopsies obtained at both
10 cm and 30 cm levels using enzymatic digestion and staining, as
previously published [54]. Biopsies were incubated in 20–25 ml
RPMI/7.5% fetal calf serum containing 0.5-mg/ml collagenase
type II (Sigma-Aldrich, St. Louis, MO) for 30 minutes in a 37uC
water bath, with intermittent shaking. The entire suspension was
then passed (up to three separate times) through a sterile plastic
strainer (BD Falcon 2350, Bedford MA) to remove free cells and
concentrate the remaining tissue fragments in a fresh 50 ml
conical tube. Free cells were immediately washed twice in medium
to remove excess collagenase, prior to being resuspended in
500 ml–1000 ml of media and set aside on ice. Monoclonal
antibodies used included anti-CD4 and HLA-DR-fluorescein
isothiocyanate (FITC), CD38, CXCR4 and CCR5–phycoerythrin
(PE), CD4 and CD45-peridin chlorophyll protein (PER-cp),
CCR5 and CXCR4-allophycocyanin (APC). All monoclonal
antibodies were supplied by BD Immunocytometry Systems
(BDIS), Mountain View, CA. Analysis was carried out on a
FACSCaliburH flow cytometry (BDIS, Mountain View, CA) with
analysis using CellQuestProH software (BDIS, Mountain View,
CA); quadrant settings were determined for well-defined popula-
tions, such as T-cell subsets, as previously described [54]. For those
populations that were less well defined, such as CD38 and co-
receptors, historical quadrant settings from prior studies were used
[49]. Percentage values for the stained subsets were recorded.
Mucosal cytokine mRNA. Cytokine mRNA for IFNc was
measured in RNA extracted from 3 pooled endoscopic biopsies,
snap-frozen in liquid nitrogen, from both the 10 cm and 30 cm
level, using a previously described technique [23,49]. Briefly,
primers optimized for qRT-PCR were designed using the cDNA
sequences of the gene of interest from the genebank database in
conjunction with Primer Express software (Applied Biosystems,
Foster City, CA). All assays were performed in triplicate and a
mean calculated from the three measurements obtained. Results
are reported as copies of cytokine mRNA standardized per 10
6
copies of b-actin.
Colonic explants for HIV-1 infectivity
Endoscopic biopsies from the 10 cm and the 30 cm site were
collected in 50 ml RPMI (with 1.125 mg/ml of Fungizone and
50 mg/ml of Zosyn, transported to the laboratory for explant set-
up, as previously reported [7,41,47,48]. Explant samples were
exposed (within 1 hour of collection) to one of two titers of the R5
Table 1. Changes in pre-defined rectal bacteria populations following cumulative exposure to 0.1% or 0.25% UC781 topical gel or
HEC placebo compared to baseline.
The percentage of each trial groups’ participants with bacteria present at baseline is listed followed by the
percentage of participants with bacterial presence following cumulative single/7-day exposures, with p values
listed.
0.1% UC781 (n=12) 0.25% UC781 (n=12) HEC (n=12)
Bacteria Baseline
Post-
exposure p value Baseline
Post-
exposure p Value Baseline
Post-
exposure p Value
Lactobacillus (H2O2-producing) 33% 50% 0.68 33% 25% 1 24% 50% 0.68
Lactobacillus (H2O2-nonproducing) 17% 17% 1 17% 0% 0.48 17% 25% 0.5
Gardnerella vaginalis 0 0 25% 25% 1 0% 8% 0.3
Escherichia coli 83% 83% 1 92% 75% 0.59 92% 92% 1
Other gram-negative rods 17% 8% 1 25% 25% 1 25% 8% 0.59
Anaerobic gram-positive cocci 92% 92% 1 100% 100% 1 83% 83% 1
Anaerobic gram-positive rods
(Clostridium)
67% 83% 0.64 83% 67% 0.64 92% 75% 0.59
Anaerobic gram-positive rods
(other)
83% 67% 0.64 67% 92% 0.32 67% 100% 0.09
Anaerobic gram-negative rods 100% 100% 1 100% 100% 1 100% 92% 1
Black-pigmented anaerobic
gram-negative rods
58% 83% 0.37 92% 83% 1 100% 83% 0.47
NB: No differences between the HEC and the UC781 exposed groups were seen. No differences in female to male cultures were seen.
doi:10.1371/journal.pone.0023243.t001
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4 TCID50 or 10
2 TCID50); TCID50 was
determined by titration using pooled PBMCs. The same viral
stock used throughout the study. Explants were incubated with
virus for 2 hours and then thoroughly washed and six explants
from 10 cm and six explants from 30 cm were placed (one biopsy/
raft) on gelfoam rafts in individual wells of a 24 well plate (CostarH
#3524, Corning, Inc., Corning, NY). Explants were followed for
14 days with supernatants for ELISA quantification of p24 (ng/ml)
collected every 3–4 days and replaced with media (100%). Results
are reported here as cumulative p24 detected at day 14 with
‘uninfectible’ defined as less than 100 ng p24/ml (p24 kits from
AIDS & Cancer Virus Program, NCI, Bethesda, MD; detection to
78 ng/ml). At baseline (Visit 2), all participants’ HIV-exposed
explant biopsies had a positive control of added UC781 to
demonstrate suppressive potential.
The following samples were collected and assessed at Visit 2, 3
&5 :
(i) rectal microflora to assess changes with swabs collected at
baseline and post 7-day exposure (only Visits 2 and 5)
(ii) sloughing of rectal epithelial cells using endoscope-
collected lavage at Visits 2, 3 & 5
(iii) histopathology at 10 cm and 30 cm at Visits 2, 3,& 5
(iv) fecal calprotectin to assess mucosal inflammation from
post-enema evacuation at Visits 2, 3 & 5
(v) mucosal mononuclear cell (MMC) phenotype by flow
cytometry at Visits 2, 3 & 5
(vi) secreted mucosal immunoglobulins collected by sponge
(total IgG, total IgA) at Visits 2, 3-pre and 3-post & 5
(vii) secreted mucosal cytokine proteins collected by sponge at
Visits 2, 3-pre and 3-post product exposure & 5
(viii) mucosal tissue mRNA cytokine profile at Visits 2, 3 & 5
(ix) biopsies for ex vivo HIV-1 explant infection Visits 2, 3 & 5.
Plasma levels of UC781
Bridge Laboratories (Gaithersburg, MD) conducted FDA GCP
compliant quantifications of plasma levels of UC781 within
concentration ranges of 0.25 ng/ml to 200 ng/ml, using a
validated LC-MS/MS system (lower limit of quantitation (LLOQ):
0.25 ng/ml). Samples evaluated included all 9 subjects (placebo
and two UC781 concentration exposure groups) randomized to
undergo the PK plasma sampling (baseline, 30 minutes, 2 hr,
4 hr, 24 hr and post 7-day exposure). Mucosal biopsies were
obtained to quantify tissue levels of UC781 once the method had
been optimized. The assay was recently validated and results
obtained. These are being analyzed and will be reported in a
subsequent paper.
Statistical Analysis
Evaluations of the different data collections were done as follow:
Analysis of baseline variability among the three treatment groups
was performed for continuous measure using analysis of variance
and Kruskal-Wallis test. This exercise assured investigators that
baseline ranges here were consistent with those previously
published by this group in HPTN-056 [49]. Paired t–test and
other appropriate tests were used to compare results from tissue
samples collected at the 10 cm and 30 cm biopsy locations
(histopathology, tissue cytokine mRNA, flow cytometry and ex vivo
explant infections). To analyze the treatment effect of the UC781
gel, changes in mucosal indices from baseline to post-single
exposure (V3) or post-7-day exposure (V5) were compared
between each of the UC781 treatment groups and the HEC
placebo group. A two sample t-test was used for continuous
variables (tissue mRNA for cytokine, fecal calprotectin, flow
cytometry). For continuous variables with two baseline measure-
ments (rectal fluid cytokine profile, immunoglobulins), a mixed
linear model with person-level random effect was used. For
categorical variables (epithelial sloughing, histopathology), 95%
confidence intervals for the difference in correlated proportions
were calculated.
Statistical Analysis of Ex Vivo Biopsy Infectibility
Suppressive impact of in vivo UC781 on ex vivo explant
infectibility assays. The aim of this explant study was to
determine whether in vivo administered topical product could
suppress ex vivo HIV-1 infection in biopsies based on the ancillary
study endpoint of cumulative p24 antigen at day 14 (already
shown to tightly correlate with qRT-PCR for HIV) [64].
Comparisons evaluated the difference in tissue infectibility
between baseline (Visit 2) and post-single dose exposure (Visit 3)
or post-7-day exposure (Visit 5) in each study group using paired t-
tests. Assessments of the treatment effect on altered infectibility
from baseline (Visit 2) to post exposure single (Visit 3) or post-
repeated (Visit 5) were conducted at each combination of biopsy
locations (10 cm and 30 cm) and viral titers (10
2,1 0
4) using two
sample t-tests. Evaluation of potential baseline differences in
biopsy infectibility (10 cm versus 30 cm) for each viral titer used
was conducted by using paired t-tests. To determine whether
treatment effect differs between the two biopsy locations, a mixed
linear model evaluating differences in cumulative day-14 p24
antigen levels was fitted. This model incorporated person-level
random effects to account for correlations among biopsies at
10 cm and 30 cm taken from the same individual. Four separate
analyses were done, one for each combination of UC781 product
(0.1%, 0.25%) and viral titer (10
2,1 0
4). The mixed model afforded
a number of comparisons, among which are a test for treatment
effect (product vs. placebo), a test for biopsy location difference
(10 cm vs. 30 cm), and a test for location6treatment interaction
(addressing whether treatment varies by biopsy location). All
biopsy infection results were independently confirmed by a
secondary analysis using a comparison of 4 alternative analyses
of explant readouts (day 14 p24, AUC, slope, and soft-endpoint
analyses [65].
Results
Participant Demographics, High Study Retention and
Sample Acquisition
The 36 subjects completed the study in 16 months, each
requiring a 7–14 week participation including 5 clinic visits, 3 visits
for flexible sigmoidoscopies and sample collection, 2 ACASIs and
1 in-depth phone interview. Of 155 potential participants
telephonically pre-screened, 55 were eligible for the screening
visit (V1) with 36 participants meeting ‘‘enrollment’’ criteria for
baseline sampling at Visit 2. All 36 participants initially enrolled
completed the study (100% retention). The median age was 41
(range: 24–64) with 26 males (72%) and 10 females (28%).
Participants were 41% African American, 39% Caucasian, 14%
Hispanic, 3% American Indian and 3% Pacific Islander. Few
differences between the participants randomized to each of the 3
study groups were appreciated (see Demographics Table S1).
No Serious (Grade 3 or 4) Adverse Events (AEs) Reported
Thirty-six AEs were reported of which 28 (78%) were Grade 1
and 8 (22%) were Grade 2. There were no Grade 3 or 4 AEs nor
any procedure-related AEs (108 flexible sigmoidoscopies with just
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AEs occurring following product exposure (Visit 3 forward) are
reported; all are described in Adverse Events Table S2 by
number/percentage of subjects having AEs, whether they were
gastrointestinal (GI) related or not and which AEs occurred during
which trial stage. Table S2 shows that the number of subjects with
AEs of any grade are similar between groups after the single or 7-
day exposure.
Nearly all the Grade 1 abnormalities (19/28; 68%) were
recorded as not related to product. Of the 9/28 (32%) Grade 1 AEs
reported as related to product, 6 were in the placebo group, 2 in the
0.1% UC781 group and 1 the 0.25% UC781 group. Eight Grade
2 AEs were reported among 5 subjects. Four of these 8 reports
were from 1 individual (#401 - placebo group) who reported fever,
cramps, flatulence, and diarrhea, considered possibly related, after
the single exposure (Visit 3). Of note, no Grade 2 AEs were seen in
this individual following the 7-day exposure. The other 4 Grade 2
AEs included the following: limited diarrhea in 2 subjects following
the 7-day exposure and considered possibly related (#414 in the
0.25% UC781 group and #418 in the 0.1% UC781 group);
transient thrombocytopenia in 1 subject following the 7-day
exposure and considered not related (#420 in the 0.25% UC781
group); and a spider bite in 1 subject after single dose and
considered not related (#432 in the placebo group).
No Epithelial Sloughing from Rectal Lavage
No significant differences at baseline (Visit 2) were identified
among enrolled subjects. No differences in the degree of epithelial
sloughing between single exposure (Visit 3) and baseline or 7-day
exposure (Visit 5) and baseline were appreciated. No UC781
treatment effect was identified for either low-concentration gel or
high-concentration gel relative to placebo.
No Changes in Histology at 10 cm and 30 cm
Neither the placebo nor either of the two UC781 gel
concentrations showed significant differences between either single
or 7-day exposure and baseline. No differences were seen when
each subject’s baseline samples at 10 cm and 30 cm were
compared using this index of inflammation.
No Changes in Rectal Microflora
No significant changes in any of the rectal microflora profiles
assessed were seen within subjects exposed to UC781 (either low or
high dose) or the HEC placebo compared to their baseline culture
results. As well, no significant differences were seen between study
groups after cumulative (single and 7-day) exposures (Table 1).
Although the study participant subpopulations were too small for
statistical evaluation, no trends toward differences were seen
between microflora samples from men compared to women
(overall) or with between-group analyses of men compared to women,
including Lactobacillus and Gardnerella vaginalis.
No Changes in Fecal Calprotectin
No significant differences in stool calprotectin, an indirect
indicator of mucosal inflammation, were seen among study
participants at baseline. No significant differences in calprotectin
within subjects or between groups were appreciated following
single-dose or after 7-day exposure (Table 2).
Minimal Changes in Mucosal Immunotoxicity Indices
The following data were studied at baseline and compared
within and between groups after single-dose and after 7-day
exposure: (i) phenotypic, HIV-1 co-receptor and activation profiles
of mucosal CD4+ and CD8+ T lymphocytes at 10 and 30 cm; (ii)
rectal fluid IgG and IgA immunoglobulins; (iii) rectal fluid cytokine
protein yields; and (iv) tissue cytokine mRNA at 10 cm and 30 cm.
These unique, baseline data from mucosal samples of healthy
HIV-1 seronegative subjects will be enormously helpful to help
power future study designs. Consequently, the detailed resultant
means and standard deviations for each set of indices are added in
Table S3.
Baseline variability was examined for all indices above. For flow
cytometric analyses, no significant result was identified among 18
baseline comparisons performed. Importantly, the findings are
consistent with those seen in the earlier HPTN-056 study [49],
aimed at defining normative mucosal ranges for immunoinflam-
matory indices. However, using paired t-tests, baseline differences
in lymphocyte surface phenotype and activation markers were
seen between 10 cm and 30 cm, as we’ve reported previously
[56,57]. Significant between-site differences at baseline (Visit 2)
were identified at a level of a=0.05 for % CD4+ T cell
lymphocytes, CD38 RFI on CD4+ T cell lymphocytes, CD38%
on CD4+ T cell lymphocytes, HLA-DR% on CD4+ T cell
lymphocytes, CCR5% on CD4+ T cell lymphocytes and %
CCR5/CXCR4 double-positives on CD4+ T cell lymphocytes.
These may reflect real differences since the total number of
comparisons here was 9 [41].
Following intervention, before-after comparisons (baseline to
single exposure or baseline to 7-day exposure) were conducted to
evaluate changes in each of the above mucosal immune indices in
each study group. From the 180 comparisons performed, 26 were
significant at a=0.1. However, at a=0.05, 11 were significant
(closer to the expected number of 9). There were no consistent
patterns seen in the distribution of these 26 results. No evidence of
consistent mucosal reaction to UC781 treatments or vehicle was
identified following either single or 7-day exposure.
Table 2 presents the group analysis results of the clinician-
delivered single-dose and self-administered 7-day exposure UC781
treatment effects compared to placebo on changes in all mucosal
immune indices. Given the relatively small sample size and given
the safety consideration of these first Phase 1 studies, we felt it
important not to overlook any possible altered findings associated
with exposure. Hence, those comparisons with p-values .10 and
lower (corresponding to an alpha of 10%), are highlighted in
Table 2, which gives a higher power for identifying significant
differences, at the cost of increased Type I error probabilities. For
single-dose UC781 treatment effect compared to placebo, on
changes in all mucosal immune indices (Visit 3-Visit 2) where 60
comparisons were performed, the single significant result
(RANTES in the 0.1% UC781 vs. placebo comparison) is not
unusual. The results support the conclusion that neither of the
UC781 gel concentrations had any significant effect on mucosal
immune indices compared to placebo. Importantly, when the
HEC placebo responses were compared to baseline after single
dose exposure (Visit 3 vs. Visit 2), no changes were identified. This
is the first such detailed assessment of the HEC placebo on rectal
mucosa (data not shown).
Following 7-day exposure (Visit 5-Visit 2), an additional 60
comparisons were compared to baseline values (Table 2). Seven
significant results were identified at a=0.1, again, not an unusual
number given the number of comparisons. The 4 findings that
may have clinical relevance were the following but need to be kept
in context with published trends toward differential expression at
baseline [41] :
(i–ii) in the higher concentration UC781 group compared to
placebo, a difference in the change of CCR5 expression was
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and 30 cm level (reduced)(P=0.025 for both)
(iii) for co-expressed CCR5/CXCR4 on CD4+ T lymphocytes
at only 30 cm (reduced) (p=0.020)
(iv) for CXCR4 alone on CD4+ T lymphocytes only at 10 cm
(reduced) (p=0.095).
It should remain clear that the selection of this broad profile of
immunoinflammatory indices of mucosal injury represents a best
effort to assess any changes of significance related to product (or
placebo) in this vulnerable compartment with few standardized
measures predicative of clinical toxicity. The overarching absence
of changes or differences is relevant.
Undetectable Plasma Levels of UC781
No detectable levels of UC781 were seen by LC-MS/MS
analysis in any samples (LLOQ in plasma: 0.25 ng/ml). As no
product was identified in the 7-day exposed participants, the only
confirmation of adherence to home use of the product was by
participant-completed diary.
Table 2. Summary of p-values for comparing changes in mucosal immune parameters compared to baseline following single or 7-
Day exposure.
Changes after single exposure
(Visit 3-Visit 2) (p-value)
Changes after 7-day exposure
(Visit 5 – Visit 2) (p-value)
UC781 0.1% vs.
Placebo
UC781 0.25% vs.
Placebo
UC781 0.1% vs.
Placebo
UC781 0.25% vs.
Placebo
Fecal Calprotectin 0.417 0.587 0.192 0.881
Mucosal Immunoglobulins
*
IgG 0.297 0.777 0.747 0.400
IgA 0.754 0.458 0.384 0.503
Cytokine
*
RANTES 0.033
*** 0.569 0.380 0.356
MIP-1 a 0.696 0.406 0.353 0.343
TNF-a 0.436 0.391 0.146 0.229
IFN-c 0.296 0.282 0.059
*** 0.211
IL-12 (p40) 0.488 0.428 0.135 0.365
IL-6 0.410 0.761 0.794 0.382
IL-1b
** 0.347 0.896 0.082
*** 0.116
Tissue mRNA for cytokine
IFN-c 10 cm 0.407 0.546 0.608 0.259
IFN-c 30 cm 0.999 0.303 0.321 0.959
Flow Cytometry: Mucosal Mononuclear Cells (MMCs)
CD4 lymphocytes 10 cm 0.561 0.806 0.380 0.497
30 cm 0.258 0.747 0.500 0.536
CD38+/HLA-DR+ on CD4 10 cm 0.467 0.404 0.392 0.946
30 cm 0.572 0.971 0.346 0.776
CD38 RFI on CD4 10 cm 0.877 0.815 0.340 0.587
30 cm 0.269 0.299 0.488 0.526
CD38% on CD4 10 cm 0.311 0.397 0.635 0.477
30 cm 0.698 0.369 0.376 0.646
HLA-DR% on CD4 10 cm 0.307 0.198 0.119 0.737
30 cm 0.419 0.749 0.984 0.643
CCR5 RFI on CD4 10 cm 0.401 0.103 0.840 0.025
***
30 cm 0.837 0.151 0.226 0.025
***
CCR5% on CD4 10 cm 0.702 0.668 0.438 0.643
30 cm 0.659 0.232 0.926 0.099
***
CXCR4% on CD4 10 cm 0.342 0.116 0.587 0.095
***
30 cm 0.511 0.211 0.533 0.112
CCR5%/CXCR4% on CD4 10 cm 0.546 0.372 0.449 0.302
30 cm 0.516 0.186 0.781 0.020
***
*For Mucosal Immunoglobulins and Cytokine, p-values were calculated based on two baseline measurements (Visit 2 and pre-Visit 3).
**One subject’s (ID=417) baseline measurements were extreme outliers and excluded from analysis.
***Statistically significant at alpha level of 0.10.
doi:10.1371/journal.pone.0023243.t002
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vivo HIV-1 Infection of Colorectal Biopsies Exposed in vivo
to UC781
Characteristics of biopsy infections at baseline (Visit
2). All 36 participants had baseline colonic biopsies obtained
from 10 cm and 30 cm immediately set up for ex vivo HIV-1
infection with R5 HIVBaL at two titers (10
4 TCID50 and 10
2
TCID50). All but one participants’ biopsies were infectible at
baseline with the higher 10
4 TCID50 viral titer. Only ,60% of
participants’ biopsies were infectible at baseline with the lower 10
2
TCID50 titer. The single individual with biopsies not infectible at
baseline with either titer (subject #439) demonstrated normal
ranges of surface CCR5 expression on mucosal CD4 T
lymphocytes by flow cytometry.
The ,40% of participants with uninfectible biopsies at baseline
with the lower TCID50 10
2 titer were not the same 40% with
uninfectible biopsies at subsequent visits. Over the course of the
trial, evaluating only the placebo group (n=12), as at baseline, all
were infectible at all visits with the higher 10
4 TCID50 titer. With
the lower 10
2 viral titer, the 33.3% (subjects #401, 407, 432, 445)
not infectible at baseline (Visit 2) was a different 33.3% subset than
those not infectible at Visit 3 (subjects #426, 432, 442, 455). At
Visit 5, 66.7% of placebo-treated explants were not infectible with
the lower viral titer (subjects #407, 416, 417, 426, 432, 442, 445,
455). With the lower viral titer, a participant’s biopsies being
uninfectible at one visit did not predict uninfectibility at later visits.
To determine whether biopsy infectibility ex vivo was impacted
by location (10 cm versus 30 cm), baseline p24 infection levels for
each titer of virus was compared, using paired t-tests. No evidence
for differences in explant infectibility ex vivo was seen between two
biopsy locations of 10 and 30 cm. These data support using a
single site in future similarly designed trials.
Single-Dose Exposure: Ex vivo infections were suppressible
following single-dose in vivo product exposure. Data are
shown in Figure 2 for the within-group suppression of cumulative p24
following ex vivo infection of participants’ biopsies when exposed in vivo
to the single dose of the topical product (Visit 3 compared to Visit 2).
These products were directly applied by study clinicians. In the
0.25% UC781 treatment group, the sharp decreases in viral
infections from Visit 2 to Visit 3 are striking. This decrease is
consistent across both virus titer levels and both biopsy locations.
The viral suppression shown in Figure 2 (right column) using the
0.25% UC781 formulation are significant at a=0.05, based on
two-sided paired t-tests for the four separate before-after
comparisons (10
2 virus at 10 cm, 10
2 virus at 30 cm, 10
4 virus
at 10 cm, 10
4 virus at 30 cm) (p,0.02). The same paired before-
after comparisons for the 0.1% UC781 formulation demonstrate a
trend toward suppression but with marginally significant or non-
significant differences (10
2 virus: p=0.69 at 10 cm, p=0.038 at
30 cm; for 10
4 virus: p=0.051 at 10 cm, p=0.035 at 30 cm).
None of the placebo comparisons showed a significant change
between Visit 2 and Visit 3.
Single exposure: Between group differences in biopsy
viral suppression. The effect of 0.25% UC781 formulation
relative to placebo was significant for 10
4 TCID50 at 10 cm
(p=0.002) and close to significant for 10
4 TCID50 at 30 cm
(p=0.059) at the significance level of a=0.05.
Seven-Day Exposure: Biopsies from 7-day, in vivo exposed
participants did not demonstrate durable suppression of ex
vivo infection. Figure 3 shows the cumulative p24 effect
following ex vivo infection of participants’ biopsies after the 7-day,
at home, self-delivered exposure of the topical product (Visit 5)
compared to baseline (Visit 2). None of the paired before-after
comparisons in either study group (0.25% UC781, 0.1% UC781,
placebo) demonstrated a significant change between Visit 2 and
Visit 5 under any combination ofvirus titers and biopsy locations.7-
day exposure: Between group differences in explant viral suppression. Between-
group reductions were also not seen following the 7-day exposure
group comparisons.
Mixed model analyses showed ‘‘treatment,’’ not biopsy
location, was responsible for the observed significant
effects. This approach addressed whether differences in the
cumulative p24 between baseline (Visit 2) and post-single exposure
(Visit 3) were primarily related to treatment and/or biopsy
location. The treatment effect was highly significant for the 0.25%
UC781 in vivo treated biopsies exposed ex vivo to 10
4 TCID50 virus
(p,0.001). The tests for biopsy location as well as
location6treatment interaction were not significant (p=0.65 and
p=0.40, respectively). The other three analyses (0.1% formulation
with 10
2 TCID50, 0.1% formulation with 10
4 TCID50, 0.25%
formulation with 10
2 TCID50) also did not show any significant
treatment, location or treatment6location effects.
Discussion
There are five main findings in this first-in-field, Phase 1,
randomized, double-blind, placebo-controlled trial of a vaginally
formulated HIV-1 microbicide used rectally in 36 men and
women: (i) The results showed both doses of the vaginally-
formulated UC781 gel used rectally are safe by every index used
and are highly acceptable to participants [50]; (ii) The design of
the trial was innovative by including two separate exposures (single
and 7-day) as independent but linked components to expedite
safety assessments; (iii) A novel profile of diverse mucosal
‘‘immunotoxicity’’ indices was included to evaluate potential
changes in colorectal mucosa following product exposure, some of
which might later point to increased risk of HIV infection; (iv) The
immunotoxicity results here correlated well with previously
published data from HPTN 056 [49], designed specifically to
identify mucosal markers of interest and their stability over 6
weeks; (v) The novel Phase 1 inclusion of ex vivo biopsy infectibility
studies based on in vivo exposed tissue samples was demonstrated as
a robust, clinically-relevant, potential early bio-indicator of
efficacy. After this trial was completed, it was decided that further
development of UC781 would not be pursued because of problems
with solubility, stability and other reasons unrelated to this trial.
However, findings (ii) through (v) above represent significant
advances in the field of microbicide development independent of
the product studied.
Colorectal mucosa is composed of a single layer of columnar
epithelial cells, extremely receptive to injury but capable of rapid
repair. It is highly vulnerable to HIV-1 infection [7,22], related to
the subjacent lamina propria which, in health, is densely populated
with activated memory T-cells expressing both CD4 and both
HIV-1 co-receptors CCR5 and CXCR4, as well as dendritic cells
(DCs) and macrophages [6,7,22,66,67]. The physiologically
inflamed tissue is more infectible per sex act (possibly by 20 to
2000-fold depending on co-STI infections, inflammation, etc) than
is the vaginal mucosa [68–70]. These differences may also increase
rectal compared to vaginal susceptibility to microbicide-induced
toxicity, potentially favoring HIV infection [16] as seen with other
sexually transmitted infections [31,33,34]. The rapidly reactive
rectal tissue responses make selecting sample study points difficult,
as evidenced by the differing reports and clinical implications seen
with N9. Tabet et al. in evaluating an approved vaginal
formulation of N9 in MSM [16], described mild to no rectal
histological changes in participants receiving up to 6 weeks of daily
N9 (or placebo gel) with samples collected up to 12 hours after N9
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histology endpoints, saw marked rectal epithelial exfoliation
15 minutes after a single N9 topical exposure in men which
disappeared after 2 hours [14].
In this Phase 1 trial, the rectally-applied, vaginally-formulated
UC781 0.1% and 0.25% gel and the HEC placebo were safe.
There were no Grade 3 or higher AEs reported nor any
procedure-related AEs despite over 3000 biopsies having been
performed. Retention was 100% post-enrollment, emphasizing
participant’s understanding and willingness to undergo these
procedures repeatedly.
Acceptability (using web-based surveys and an in-depth
interview at study’s end) was high, especially when focusing on
‘‘likelihood’’ to use the product in the future [50]. The importance
of determining acceptability in the early phases of microbicide
development is critical, enabling earlier, less costly product
changes and raising the likelihood of real-life use.
The ‘‘immunotoxicity assays’’ as a whole, showed no significant
changes from baseline for each product or any significant
differences between study groups. This was true for both the
10 cm and 30 cm assessments following the single-dose and the 7-
day dose exposures. It is reassuring that the baseline results here
were generally within the normative ranges reported in HPTN
056 [49]. This confirmation is important to the field.
One of the most impactful endpoints in this Phase 1 trial was the
first-time attempt to infect ex vivo tissue biopsies that had been
exposed to drug only in vivo. Given limits on the number of biopsies
obtainable, only the laboratory strain of R5 HIVBaL was used at
two titers (TCID50 of 10
4 and 10
2 using the same lot of virus).
These titers are thought to be far in excess of ejaculate
concentrations [43–45]. Colorectal explant techniques have been
increasingly used for HIV-1 infectibility readouts from a variety of
tissue types [64,71,72] and evaluated in a multi-center standard-
ization process conducted within the NIH sponsored Microbicide
Quality Assurance Program [65]. Currently, there are two freshly-
acquired, colorectal explant models: the ‘‘sealed edge’’ model
optimizing polarization and orientation for virus exposure [73]
and the ‘‘exposed edge’’ model [41] which simply places the
explant on a gelfoam raft, with virus access to all surfaces. This
trial utilized the second model as we felt it more accurately
reflected clinically relevant situations where preparatory enemas
and rectal intercourse are often traumatic to the epithelia,
potentially providing HIV with direct access to sub-epithelial
target cells.
The higher viral titer reproducibly infected nearly all subjects’
colorectal biopsies at baseline while the lower viral titer infected
only 60%. Notably, the 40% not infectible with this lower titer at
baseline were not always the same 40% uninfectible at later time
points (placebo arm). This supports an interpretation that infection
at this titer (closer to clinically relevant titers) could be a statistically
random event or reflect intra-subject biological variables, such as
innate defenses, at the mucosal surface. For use in smaller,
exploratory and Phase 1 trials, if baseline infectibility is needed to
optimize power calculations and smaller enrollment numbers, it
appears a higher viral titer would be preferred to insure baseline
infectibility.
Evaluating the data from the directly-applied, single
topical gel exposure
Statistically significant suppression of ex vivo biopsy infections
was seen in the high-concentration gel group (0.25%) after a single
exposure compared to baseline. This was seen with both the high
and low titered virus. Between-group comparisons (UC781 gel
compared to placebo) demonstrated that the treatment effect was
significant, even with these small subject numbers. This was seen
only with the higher viral titer. The data are compelling when
evaluating the 30 minute topical exposure of the higher UC781
concentration (0.25% gel) at 10 cm (area most likely drug exposed)
using the higher viral titer (assuring baseline infectibility). UC781 is
a potent inhibitor of viral RT. For this to be the main mediator of
suppression in these heavily washed biopsies, other mechanisms
may need to be invoked and tested, including an intracellular
activity and/or retained drug in tissue/membranes due to the
lipophilic nature of UC781 inhibiting further replication. This
latter observation is the known (but poorly understood) ‘‘memory’’
effect of UC781. A clinically relevant advantage may be prolonged
resistance to transmission due to this feature of UC781, possibly
allowing for coitally-dissociated administration.
These results showing suppression of ex vivo biopsy infection
were consistent and reproducible, within groups and between
groups. Given that these are clinical samples with expected inter-
subject variability and washed frequently by shaking in media and
during transport from the endoscopy unit to the laboratory, it is
remarkable that any ex vivo impact was seen with only 12
participants in each study group. Additional confounders (that
might have taken years to segregate out) include in vivo variables
such as the biological activity of the colorectal area (continuous
mucus secretion, peristaltic activity, frequent stool passage) and the
absence of an independent, visual identifier to guide biopsy
acquisition relative to where the investigator-administered topical
drug might be located 30 minutes after exposure.
Evaluating the 7-day (uncontrolled) exposure
As no independent, reliable biological indicator of home
delivery/compliance was used (a great need in this field), there
are many contributory explanations for the apparent absence of ex
vivo suppression of biopsy infections. Maintained suppression
would be dependent on the subjects using the product daily, as
instructed, and that there be some tissue penetration/retention,
given the active GI elimination processes. In addition, some of the
biochemical, lipophilic features of UC781 as well as its tissue half-
life in vivo remain undefined. When coupled with complex mucosal
factors of mucus, microflora and dynamic epithelial turnover, the
absence of 7-day exposed ex vivo suppression is more understand-
able and points out challenges to address in future trials.
At this point, the ex vivo biopsy infection suppression assays
may be viewed as a possible bioindicator of pre-clinical efficacy.
Importantly for future trials: (i) no differences were seen using
the 30 cm or the 10 cm biopsies, supporting the selection of a
single anatomical site in similarly designed trials (benefiting
participant safety as well) and (ii) using a sufficiently high titer of
Figure 2. Changes in ex vivo infectibility of rectal biopsies following single exposure. The graphs document the impact of the in vivo
delivered HEC placebo gel, 0.1% UC781 gel or the 0.251% UC781 gel on suppressing ex vivo HIV-1 tissue infection. Changes in cumulative p24 antigen
at day 14 from biopsies at Visit 2 and Visit 3 are reflective of relative degrees of replicative activity of either low (10
2 TCID50) or high (10
4 TCID50) titer
HIV-1BaL in biopsies from either 10cm or 30cm (p values in lower left corner of each figure) after a confirmed 30 minutes of in vivo exposure to the
defined product.
doi:10.1371/journal.pone.0023243.g002
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baseline samples.
Conclusions
The microbicide field has met with significant difficulties in
attempting to move a product from design through development
to demonstrating efficacy. The first hopeful signs were the
dramatic results from CAPRISA 004 [10]. While not discussed
much 10 years ago, awareness of the high prevalence of receptive
anal intercourse (RAI) in heterosexual partnering [24–30,74–80]
as well as MSM, combined with the enhanced infectibility per sex
act of this compartment has driven the microbicide field to actively
include development, assessment and acceptability of rectal
microbicides into the main portfolio of scientific and public health
goals.
Many advances in technology, immunotoxicity assessments, PK
and pharmacodynamic (PD) study design, formulations and
acceptability measures have enabled the development of
more strategic and focused efforts with rectal microbicides
[41,46,47,49,54,63,64,81–85], supporting a rapid advance to
clinical trials. While development of a combination microbicide
useable in both sexual compartments is a long-term desired goal,
the current need for a safe and effective rectal microbicide is
evident. The inclusion of a novel ex vivo biomarker of efficacy in a
Phase 1 trial is a boon to the field and may turn out to be an
exciting addition as a ‘‘nonclinical surrogate of bio-efficacy,’’
helping guide decisions about which agents at which concentra-
tions should be advanced in human trials. These intensive efforts
and mucosal indices benefit the microbicide field as well as the
growing focus on mucosal vaccines, enabling a more rational and
cost-effective product development pipeline.
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